Description: Pirtobrutinib (LOXO-305) is an advanced BTK inhibitor that displays high selectivity and operates through a non-covalent mechanism. This compound effectively inhibits various BTK C481 substitution mutations, leading to tumor regression in BTK-dependent lymphoma tumors in mouse xenograft models....

Pirtobrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). It inhibits wild-type and mutant BTK (IC50s = 10-100 and C481S, respectively). It is selective for BTK over EGFR (IC50 = 1-10 µM). Pirtobrutinib decreases the number of Ki67-positive cells, a marker of cell proliferation, in MEC-1 chronic lymphocytic...